SCHEMBL43076

SCHEMBL43076

COC(=O)c1occc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.53
THRB P10828 1/20 0.53
MEN1 O00255 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
GAA P10253 2/20 0.44
PKM P14618 1/20 0.44
NAMPT P43490 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
CHRNB2 P17787 2/20 0.41
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
CHRNA4 P43681 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69723 0.83 HSD17B10 (0.44) KDM4EMAPTALDH1A1MEN1RAB9A
SCHEMBL27516023 0.83 KDM4E (0.49) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL31310778 0.82 HSD17B10 (0.43) KDM4EMAPTALDH1A1MEN1RAB9A
SCHEMBL26622083 0.82 KDM4E (0.47) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL27904144 0.82 KDM4E (0.47) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL1257007 0.80 MAPT (0.50) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL20101950 0.79 KDM4E (0.41) KDM4EMAPTALDH1A1THRBSMN1; SMN2
SCHEMBL28244480 0.79 KDM4E (0.57) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL10417495 0.78 KDM4E (0.55) KDM4EMAPTALDH1A1THRBMEN1
SCHEMBL22068300 0.78 CHRNA4 (0.48) KDM4EMAPTALDH1A1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119930868-A Catalyst component containing furoic acid ester compound, preparation method thereof, olefin polymerization catalyst, olefin polymerization method and olefin polymer 中国石油化工股份有限公司 2025-05-06 CN claimed
EP-4739688-A2 TRIAZOLO WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-05-13 EP disclosed
EP-4727942-A2 THIAZOLOPYRIDIN-7(4H)-ONE WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-04-22 EP disclosed
EP-4724446-A1 OXAZOLOPYRIDIN-7(4H)-ONE WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-04-15 EP disclosed
EP-4724070-A2 WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-04-15 EP disclosed
US-12528806-B2 WRN inhibitors NIMBUS WADJET, INC. (US) 2026-01-20 US disclosed
CN-121248488-A Quaternary ammonium salt derivative containing thymol, preparation method, drug-loaded antibacterial liposome and application thereof 贵州大学 2026-01-02 CN disclosed
US-20250388568-A1 NLRP3 INHIBITORS KODIAK SCIENCES INC (US) 2025-12-25 US disclosed
US-12421233-B2 WRN inhibitors NIMBUS WADJET, INC. (US) 2025-09-23 US disclosed
US-12344609-B2 WRN inhibitors NIMBUS WADJET, INC. (US) 2025-07-01 US disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 EP disclosed
EP-1242426-A1 GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS Merck & Co., Inc. (US) 2002-09-25 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed
WO-2001038332-A1 GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS MERCK & CO., INC. (US) 2001-05-31 WO disclosed
US-5693827-A Treatment of HIV infections and compounds useful therein UNIROYAL CHEMICAL COMPANY, INC. 1997-12-02 US disclosed
EP-0497816-B1 TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN UNIROYAL CHEMICAL LTD (CA) 1995-05-17 EP disclosed
US-5268389-A Containing a benzene ring UNIROYAL CHEMICAL COMPANY, INC. (US) 1993-12-07 US disclosed
EP-0497816-A1 TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN. UNIROYAL CHEMICAL LTD (CA) 1992-08-12 EP disclosed
WO-1991005761-A1 TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN UNIROYAL CHEMICAL LTD./UNIROYAL CHEMICAL LTEE (CA) 1991-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 KDM4E 3250/4885MAPT 1878/4885ALDH1A1 534/4885
US-12421233-B2 WRN inhibitors WRN, BLM, RECQL KDM4E 3350/4885MAPT 3795/4885ALDH1A1 3002/4885
US-12344609-B2 WRN inhibitors WRN, BLM, RECQL KDM4E 2662/4885MAPT 3802/4885ALDH1A1 3196/4885
US-20250388568-A1 NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 KDM4E 4287/4885MAPT 197/4885ALDH1A1 3213/4885
US-12528806-B2 WRN inhibitors WRN, RECQL, BLM KDM4E 1099/4885MAPT 3335/4885ALDH1A1 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.